Progen Co., Ltd.

Rani Therapeutics Achieves Bioequivalence with Oral GLP-1/GLP-2 Dual Agonist for Obesity Treatment

2 months ago

• Rani Therapeutics demonstrated that RT-114, an oral GLP-1/GLP-2 dual agonist delivered via RaniPill® capsule, achieved 111% bioavailability compared to subcutaneous injection in preclinical studies, with comparable weight loss outcomes. • The company's RaniPill® platform has successfully delivered four incretin-based molecules orally, including semaglutide, positioning Rani to potentially transform obesity treatment by eliminating the need for injections. • A Phase 1 clinical trial for RT-114 is expected to begin in mid-2025, with the company aiming to develop the first-in-class oral GLP-1/GLP-2 dual agonist for obesity treatment.